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AbstrACt
Introduction Observational data suggest a single high-
sensitivity troponin blood test taken at emergency department 
(ED) presentation could be used to rule out major adverse 
cardiac events (MACE) in 10%–60% of ED patients with chest 
pain. This is done using an ‘undetectable’ cut-off (the Limit 
of Detection: LoD). We combined the LoD cut-off with ECG 
findings to create the LoDED strategy. We aim to establish 
whether the LoDED strategy works under real-life conditions, 
when compared with existing strategies, in a way that is cost-
effective and acceptable to patients.
Methods and analysis This is a parallel-group pragmatic 
randomised controlled trial across UK EDs. Adults presenting 
to ED with suspected cardiac chest pain will be randomised 
1:1. Existing rule-out strategies in current use across study 
centres, using serial high-sensitivity troponin testing, will be 
compared with the LoDED strategy. The primary outcome is 
successful early discharge (discharge from hospital within 
4 hours of arrival) without MACE occurring within 30 days. 
Secondary outcomes include initial length of hospital stay; 
comparative costs; patient satisfaction and acceptability 
to patients. To detect a 9% difference between the early 
discharge rates (assuming an 8% rate in the standard care 
group) with 90% power, 594 patients need to be recruited, 
assuming a 95% follow-up rate.
Ethics and dissemination The study has been approved 
by the Frenchay Research Ethics Committee (reference 
18/SW/0038). Results will be published in an international 
peer-reviewed journal. Lay summaries will be made 
available to patients.
trial registration number ISRCTN86184521; Pre-results.
IntroduCtIon
The number of patients attending emer-
gency departments (ED) across England 
and Wales continues to rise, with over 
22 million attendances in 2014.1 Chest pain 
makes up nearly 10% of ED attendances 
and is the most common reason for emer-
gency hospital admission.2 The majority of 
patients with chest pain have prolonged 
hospital stays during which they undergo 
testing to rule out acute myocardial infarc-
tion (AMI), yet 90% of patients are found 
to have a benign cause of chest pain, such 
as gastro-oesophageal reflux.2 Prolonged 
assessment leads to increased National 
Health Service (NHS) costs, patient anxiety 
and ED crowding.3 
The need for prolonged assessment is 
driven by limitations in current diagnostic 
strategies. Clinicians rely on three elements 
to rule out AMI: patient history, ECG and 
strengths and limitations of this study
 ► The safety of the LoDED strategy, using a single 
high-sensitivity troponin blood test to rapidly ex-
clude acute myocardial infarction, is supported by 
extensive observational research.
 ► This pragmatic multicentre randomised controlled 
parallel group trial is designed to detect a meaning-
ful improvement in the rate of safe early emergency 
department  discharge using the LoDED strategy, 
when compared with usual care.
 ► Sites will use a variety of usual care pathways and 
high-sensitivity troponin assays to enhance the gen-
eralisability of the findings.
 ► Although blinding of clinicians and patients will not 
be possible, participants will be randomised before 
troponin results are known to the treating clinician 
and those performing the outcome assessment data 
analysis will be blinded.
 ► We will undertake an integrated qualitative study to 
examine patient satisfaction.
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blood test biomarkers. Patient history is an unreliable 
predictor of AMI,4 and few patients (14%) have an ECG 
that is diagnostic.2 Therefore, the majority of patients 
require biomarker testing. The current biomarker used 
to rule out AMI is troponin, a protein released into the 
blood when myocardial injury occurs. Highly sensitive 
troponin (hs-troponin) assays have been developed 
recently, meaning that very low concentrations can be 
measured.5 This has led to improved diagnostic accuracy 
earlier after chest pain onset.6 Current consensus guide-
lines recommend that rule-out hs-troponin testing can 
be undertaken using two samples taken at presentation 
and 1–3 hours later.7 8 Due to limitations in clinical and 
laboratory processing times, with strategies reliant on two 
blood tests, most patients are not discharged until at least 
4 hours after ED attendance.9 A substantial proportion 
of patients could potentially be discharged much earlier 
with a single hs-troponin test taken at presentation to the 
ED.10
It has been proposed that a single hs-troponin test at 
presentation to the ED could be used to rule out AMI 
in 9%–60% of patients with very high diagnostic accu-
racy,11–17 using an ‘undetectable’ cut-off for ruling out 
AMI. This undetectable cut-off is called the Limit of 
Detection (LoD; lowest analyte concentration at which 
detection is feasible). Current data supporting the LoD 
cut-off are from observational studies and in patients 
who were not actually discharged based on hs-troponin 
results. Evaluating new diagnostic technologies with 
observational research alone has important limitations. It 
is possible that beneficial effects will be diluted because 
clinicians do not abide by their recommendations.18 
Furthermore, unanticipated effects such as rebound 
overuse of resources have previously been reported and 
have meant that apparently safe strategies are not cost-ef-
fective.19 Therefore, the clinical and cost-effectiveness of 
the LoD cut-off remains unknown.
There are two hs-troponin assays currently approved 
by the National Institute for Health and Care Excellence 
(NICE): Roche hs-troponin T and Abbott hs-troponin 
I.7 The majority of centres within the Limit of Detection 
of Troponin and ECG Discharge (LoDED) study use the 
Roche hs-troponin T assay, reflecting current UK prac-
tice (information from manufacturer). The LoD for this 
assay is <5 ng/L. Some centres use the Abbott hs-troponin 
I assay with LoD of <2 ng/L. In addition, an emerging 
hs-troponin I assay (Beckman Coulter Access hs-troponin 
I) meets criteria to be defined as a high-sensitivity assay 
but is yet to be evaluated by NICE.20 Similarly, the LoD for 
this assay is <2 ng/L. Performance of all three assays at the 
LoD appears similar, with similar proportions of patients 
being eligible for safe early discharge.15–17 21 The LoD 
alone does not have the required diagnostic accuracy for 
clinical implementation.13 However, combining the LoD 
with ECG findings improves diagnostic accuracy (the 
LoDED strategy). In a meta-analysis of over 9000 patients 
evaluating the LoDED strategy with hs-troponin T, pooled 
sensitivity for 30-day major adverse cardiac events (MACE) 
was 98.0% (95% CI 94.7% to 99.3%), with 30% of patients 
eligible for early discharge.16 For the Abbott hs-troponin I 
assay, an analysis of 3155 patients showed a pooled sensi-
tivity for MACE of 97.9% (95% CI 95.4% to 99.2%), with 
25% of patients eligible for discharge.15 For the Beckman 
hs-troponin I assay, sensitivity for the rule-out of AMI has 
been shown to be >99%, in an analysis of 1871 patients, 
with 34% of patients eligible for discharge.17 These data 
demonstrate the efficacy (safety) of the LoDED strategy, 
yet they are all from observational cohort studies, where 
no patient was discharged based on their recommenda-
tions; therefore, the clinical effectiveness of the LoDED 
strategy across populations remains unknown.
The 2016 update to the NICE ‘chest pain of recent 
onset’ guidelines also supports the use of hs-troponin with 
a cut-off at the LoD. However, the strategy recommended 
by NICE requires that the LoD cut-off be combined with 
a risk score,22 such as the Thrombolysis in Myocardial 
Infarction (TIMI) score,23 rather than a normal ECG as we 
propose in the LoDED strategy. External validation of the 
NICE approach demonstrated that approximately 15% of 
patients will be suitable for early discharge, in contrast to 
approximately 30% using the LoDED strategy.21
The LoDED strategy is a straightforward diagnostic 
tool and current observational evidence suggests it is safe 
for implementation. The question this trial will answer is 
whether the LoDED strategy works when implemented in 
practice, with clinicians actually discharging patients early 
in significant numbers, without rebound increases in down-
stream costs and in a way that is acceptable to patients.
MEthods And AnAlysIs
study design and conduct
This is a pragmatic, multicentre, randomised controlled 
parallel group trial in adult patients presenting to the ED 
with suspected cardiac chest pain and who trigger the 
chest pain investigation pathway. Five hundred and nine-
ty-four participants will be randomised in a 1:1 ratio to 
be managed according to the LoDED strategy (allowing 
discharge after a single hs-troponin test at presentation 
to ED if a participant has no new ischaemic ECG changes 
and the hs-troponin is below the LoD) or the usual care 
rule-out strategy in current clinical use at each study site. 
Usual care will usually include two hs-troponin blood tests 
taken between 1 and 6 hours after presentation and may 
vary between sites.
This is an open study. Participants’ study allocations 
will only be blinded to those performing central review 
of data for the assessment of outcomes and the statisti-
cian analysing the results. All patients will be consented 
and randomised before their initial hs-troponin results 
are known. Patients will be ineligible to participate in 
the trial once the initial hs-troponin result is known to 
the treating clinician in order to prevent selection bias. 
The decision to discharge a patient will be made after 
clinical assessment by the treating clinician. In the event 
of ongoing clinical concern, the clinician may proceed 
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with further testing and/or admission at their discre-
tion, and contrary to the allocated strategy. Information 
on protocol adherence will be collected to facilitate a 
per-protocol analysis as well as the primary intention-to-
treat analysis.
The key objective of this study is to conduct a 
randomised controlled trial (RCT) of the LoDED 
strategy versus usual care to compare the proportion of 
patients successfully discharged within 4 hours of arrival, 
with no MACE during the following 30 days. We will also 
measure admission rates, hospital bed usage, length of 
stay, resource use and patient satisfaction, facilitating 
a health economic evaluation, and determine whether 
the LoDED strategy is acceptable to patients through 
qualitative interviews.
Day-to-day trial management is administered through 
the UKCRC-registered Peninsula Clinical Trials Unit 
(CTU) at Plymouth University and sponsored by North 
Bristol NHS Trust.
Participant flow
Participant flow is summarised in the LoDED trial flow 
diagram (figure 1).
study population and setting
Participants will be recruited from adult (aged 18 and 
over) patients attending these EDs with chest pain who 
trigger the cardiac chest pain investigation pathway, 
that is, the treating clinician intends to perform investiga-
tions to rule out a cardiac cause. Full inclusion and exclu-
sion criteria for the trial are detailed in box 1. The trial 
Figure 1 Limit of Detection of Troponin and ECG Discharge (LoDED) trial flow diagram.
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will run from 1 December 2017 until 1 December 2019. 
Recruitment for the trial has commenced (4 June 2018).
screening, recruitment and consent
Patient screening and recruitment, delivery of the inter-
vention and recording of outcomes will all be carried out 
within participating UK NHS EDs. Potentially eligible 
patients will be identified at the time of arrival in the ED 
by clinical staff or research nurses. During triage or initial 
assessment the patient will be given the written study 
participant information sheet (PIS) by a member of the 
ED clinical team or research nurse. This may be before 
the chest pain investigation pathway has been triggered, 
so that a number of patients who have been given the 
PIS to read may subsequently be ineligible to enter the 
study. Due to the time taken for laboratory processing 
of blood samples (>60 min after presentation) and time 
waiting to be assessed by a doctor, it is anticipated that 
eligible participants will have over 1 hour to consider the 
PIS prior to being approached for consent.
Patients will be screened for inclusion in the study by 
clinical staff or research nurses, and fulfilment of initial 
eligibility criteria will be recorded on a study-specific 
screening form. The written consent process will be 
undertaken by an appropriately trained (Good Clinical 
Practice; GCP) attending clinician or an appropriate 
member of the research team depending on individual 
circumstances.
Once any questions have been answered satisfactorily, 
patients who are eligible and willing to participate in the 
study will be asked to complete and sign a consent form, 
which will be countersigned by the staff member receiving 
consent. A record of the patient’s consent to participate 
will be documented in the patient’s ED records, using a 
pre-prepared sticker. A copy of the completed consent 
form should be provided to the patient, a copy filed in the 
investigator site file and a further copy will be filed with a 
copy of the study PIS in the participant’s ED records.
Clinical procedures
Study participants will have undergone the standard 
clinical assessment of ED patients with chest pain. This 
includes a triage history, routine initial observations of 
pulse, blood pressure, respiratory rate, oxygen satura-
tion and the recording of a 12-lead ECG. Standard clin-
ical practice dictates that routine blood sampling for the 
assessment of full blood count, urea and electrolytes and 
troponin is undertaken at presentation.
Baseline ECG
A baseline 12-lead ECG will be recorded in all patients 
with chest pain as part of standard clinical care. Patients 
identified by treating clinicians as having an ECG diag-
nostic of an ST-elevation myocardial infarction or 
evidence of new ischaemia (new T wave inversion >3 mm 
or ST depression >1 mm) will be ineligible.
Baseline blood sampling
All participants will have a blood sample taken for hs-tro-
ponin measurement on, or shortly after, ED arrival as part 
of the standard clinical assessment of patients with chest 
pain. No additional blood sampling is required for study 
purposes. All study centres have access to hs-troponin 
assays which already form part of standard care.
Given the pragmatic nature of the trial, ‘presentation’ 
blood sampling will be defined as the first blood sample 
taken after arrival in the ED. Blood sample results will not 
be delayed for trial purposes.
Standard laboratory reporting of hs-troponin results 
and other routine baseline blood tests will be used for 
both clinical assessment and for data collection purposes. 
At all sites this is through an electronic clinical record. 
Data from the laboratory system will be anonymously 
recorded within the case report form (CRF).
Repeat troponin tests
The default strategy will be existing rule-out strategies 
used in study centres (the control group). Therefore, a 
second hs-troponin test may be taken within these strat-
egies so as not to delay routine clinical care. However, if 
allocation is to the LoDED strategy, clinicians will not be 
required to obtain the results of the second hs-troponin 
test and immediate discharge can occur.
box 1 limit of detection of troponin and ECG discharge 
(lodEd) trial inclusion and exclusion criteria
Inclusion criteria
 ► Age ≥18 years.
 ► Presenting to the emergency department (ED) with chest pain and 
triggering the chest pain investigation pathway, that is, the treat-
ing clinician intends to perform investigations to rule out a cardiac 
cause.
 ► Peak symptoms occurred <6 hours prior to presentation to the ED.
Exclusion criteria
 ► ST-elevation myocardial infarction or ischaemic ECG (new T wave 
inversion >3 mm or ST depression >1 mm) as judged by the treating 
clinician.
 ► Clear non-acute coronary syndrome (ACS) cause for chest pain 
found at presentation (eg, pulmonary embolism, pneumonia, aortic 
dissection).
 ► Initial hs-troponin result known to the treating clinician.
 ► Hospital admission indicated due to other medical/social reasons.
 ► Chest pain due to arrhythmia (new-onset atrial fibrillation, atrial flut-
ter, sustained supraventricular tachycardia, second-degree or com-
plete heart block, or sustained or recurrent ventricular arrhythmias).
 ► Unable to provide written informed consent (lacks capacity).
 ► Unwilling to provide written informed consent.
 ► Pain too severe to provide written informed consent.
 ► Follow-up will be impossible, for example, lives abroad or no fixed 
abode.
 ► Previous inclusion in the study.
 ► Prisoners.
 ► Pregnancy.
 ► Pre-existing renal failure requiring dialysis.
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Laboratory analysis
Clinical blood samples will be analysed locally in central 
hospital laboratories for the Elecsys hs-troponin T assay 
(Roche Diagnostics, 99th percentile 14 ng/L, coeffi-
cient of variation <10%, LoD 5 ng/L), Architect STAT 
high-sensitive troponin I (Abbott Diagnostics, 99th 
percentile cut-off of 26 ng/L, coefficient of variation 4%, 
LoD 2 ng/L) or Access hs-troponin I (Beckman Coulter, 
99th percentile cut-off of 18 ng/L, coefficient of varia-
tion <10%, LoD 2 ng/L).5 20 Results will be made avail-
able to clinicians using laboratory reporting systems as 
per routine clinical care.
randomisation
After written consent has been obtained, participants will 
be randomised to be evaluated using either the existing 
rule-out strategy used in study centres (control) or the 
LoDED strategy (intervention) in a 1:1 ratio. The CTU, 
in conjunction with the study statistician, will provide 
web-based randomisation, stratified by centre and mini-
mised by age and gender.
To randomise a participant, the recruiting doctor, ED 
nurse or research nurse will access the secure website 
and enter brief participant details (initials, date of birth, 
gender, study site). Once the randomisation process is 
complete, the computer screen will indicate which diag-
nostic strategy to follow, including details of the local 
rule-out strategy for control participants as a reminder 
for site staff. A printout of the allocation generated by 
the randomisation website will be taken and filed in the 
participant’s ED records.
trial interventions
Participants fulfilling the inclusion criteria will be 
randomised to be managed according to the existing 
local rule-out strategy (control) or the LoDED strategy 
(intervention).
Usual rule-out strategies (control)
Usual care varies between study sites but includes ECG on 
arrival and usually two hs-troponin tests. All sites take the 
first sample at presentation, but the minimum time delay 
between the two samples varies. The existing rule-out 
strategy in use at each study site will be documented at 
study commencement and filed in the relevant investi-
gator site file.
LoDED strategy (intervention)
Participants randomised to the LoDED strategy will be 
eligible for discharge after a normal ECG and single 
hs-troponin test at presentation to the ED if the hs-tro-
ponin is below the LoD for the assay in use at the study 
centre.
Any participant not fulfilling this discharge crite-
rion will revert to the existing rule-out strategy in use at 
that study site and have a second hs-troponin test after 
1–6 hours as per usual care.
Postintervention procedures
Clinical management
Once hs-troponin results are available (for either control 
or intervention pathways) the discharge decision will be 
entirely at the discretion of the treating clinician. Onward 
referral for outpatient investigation, such as chest pain 
clinics, will follow local guidance and will not be altered 
for trial purposes.
Participant advice
All participants discharged according to the LoDED 
strategy will be given a study-specific leaflet containing 
written information about the tests they have had during 
their stay and what to do should their chest pain returns, 
or if they have any concerns (online supplementary mate-
rial). Feedback will be sought during the study on the 
content of this information leaflet and its wording refined 
for patient use if the LoDED strategy is adopted clinically 
(integrated qualitative study).
Patient satisfaction survey and EQ-5D
All participants, irrespective of group allocation, with the 
exception of those admitted to an inpatient ward bed for 
further clinical management, will be asked to complete 
a bespoke written patient satisfaction questionnaire on 
discharge from the ED (or ED observation ward; EDOU) 
to compare treatment satisfaction between the two study 
groups.19
Participants with an initial hs-troponin below the LoD 
(irrespective of group allocation) will also be asked to 
complete a baseline EQ-5D health status questionnaire 
on ED/EDOU discharge, repeated at 30 days.24
outcomes
Primary outcome
The primary outcome is successful early discharge, 
defined as discharge from hospital within 4 hours of ED 
arrival, without MACE occurring within 30 days.
The safety endpoint of MACE occurring within 30 
days, included within the primary outcome, will be 
defined as cardiac death, AMI or emergency revascu-
larisation occurring within 30 days of ED attendance 
(including the index presentation). AMI will be defined 
according to the universal definition, which states that 
a rise and/or fall of troponin above the 99th percentile 
value confirms the diagnosis.25 A significant rise and/or 
fall will be defined as an absolute change in troponin 
over time of at least half the 99th percentile value of the 
assay in clinical use.26
Secondary outcomes
Secondary outcomes will include: length of ED/EDOU 
stay, measured in hours, hospital admission and subse-
quent length of stay, incidence of MACE occurring within 
30 days of ED attendance, comparative costs, participant 
satisfaction (quantitative survey) and acceptability to 
patients (qualitative methodology).
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Follow-up processes
Participants with an hs-troponin at presentation below the LoD
All participants with an initial hs-troponin below the LoD 
(irrespective of group allocation) will be followed up 
by telephone by the research nurse, or by email, at 30 
(+5) days after index presentation to capture informa-
tion about any adverse events and any primary care or 
secondary care health service use since discharge from 
the ED.
If the participant indicates that they have attended any 
health service provider for any reason since discharge 
from the ED, but there is concern over patient recall of 
events, then research nurses will review hospital records 
(where available) to verify outcomes.
Remaining participants
Participants with an initial hs-troponin above the LoD 
will be sent a screening text message after 30 (+5) days by 
the study team. This text will ask: ‘Since you came to the 
Emergency Department with chest pain have you needed 
to see your GP or re-attend an Emergency Department 
or visit an outpatient clinic for assessment of chest pain?’ 
Patients answering ‘No’ will require no further follow-up. 
Participants who fail to respond, or answer ‘Yes’, will 
be followed up by telephone by the research nurse or 
routine data will be collected from local hospital elec-
tronic patient records on initial diagnosis, local reatten-
dance and outpatient follow-up.
Outcome adjudication
Incidence of MACE occurring within 30 days of ED atten-
dance will be recorded on a serious adverse event (SAE) 
form by the local principal investigator or designee with 
reference to relevant clinical information and responses 
to 30-day follow-up telephone assessments uploaded to 
the study database. All participant data will be reviewed 
by an independent adjudication committee at the end of 
the study to confirm the primary outcome.
sample size
Current observational research gives estimates of the 
proportion of patients with an hs-troponin <LoD in the 
intervention group of the RCT (LoDED strategy) of 
between 10% and 60%.11–17 UK observational data suggest 
that these patients will be discharged within a median time 
of 3.5 hours (taking into account laboratory processing 
and 60 min of decision-making time).10 Data provided to 
us from a recent pragmatic RCT evaluating a 0/2-hour 
hs-troponin rule-out strategy have demonstrated that only 
10% of patients will be discharged within 4 hours using this 
approach.9 Clinical protocols using rule-out strategies at 
later time points (eg, 3 hours) will be expected to have even 
fewer patients discharged within the 4-hour time frame; simi-
larly the 0/1-hour strategy may realise a marginal increase 
in discharges before 4 hours. These differences have been 
taken into account within the power calculation. For the 
overall population we anticipate 8% will be discharged 
within 4 hours using usual care and at least 17% using the 
LoDED strategy. Therefore, this study will be powered to 
detect a 9% difference between the early discharge rates 
with 90% power and 5% statistical significance. This will 
require 282 patients in each group and 564 patients in total 
with primary outcome data. Assuming a 95% follow-up rate, 
594 patients need to be recruited. Recruitment will take 
place over a 9-month period.
data analysis
All analyses will be conducted blind to group allocation. 
A Consolidated Standards of Reporting Trials diagram 
will be used to report the number of patients screened, 
recruited and randomised.27 It will also detail the number 
allocated to each group and the frequency of the primary 
outcome.
The primary outcome of discharge within 4 hours will be 
analysed by logistic regression using all those randomised 
in an intention-to-diagnose analysis. The analysis will be 
stratified by centre to allow for differences between the 
proportions discharged within 4 hours in the control 
group at each of the study sites. Heterogeneity of the odds 
of early discharge at each centre will be investigated and 
only pooled if appropriate. The OR of early discharge 
controlling for age, sex and centre will be presented with 
a 95% CI for each centre individually and combined 
across centres. In the event of significant heterogeneity 
in the control group but homogeneity within the inter-
vention group the results will be presented as the rate of 
early discharge in the intervention group together with 
95% CIs. Adherence to the allocated rule-out strategy will 
be presented as percentage with 95% CIs.
The analysis of the quantitative secondary outcomes 
will also control for age, sex and centre, with a multiple 
regression analysis and difference in means reported for 
the comparison of length of hospital stay between groups 
and for the total score from the patient satisfaction 
survey obtained from summing the individual items. The 
responses for the individual items of the patient satisfac-
tion survey will also be reported by group, but an adjusted 
analysis will not be carried out.
The incidence of MACE occurring within 30 days of ED 
attendance in those discharged according to the LoDED 
strategy versus usual care will also be reported with 95% 
CIs. As the event rate is expected to be low, it is unlikely to 
be possible to carry out an adjusted analysis. There are no 
preplanned interim analyses. A secondary per-protocol 
analysis will also be performed for the primary outcome.
health economic analysis
The primary economic analysis will include all 
randomised participants (intention-to-diagnose anal-
ysis) and compare secondary care costs. Secondary care 
resource use will be valued using national sources of unit 
costs. A subgroup analysis will provide extra detail on the 
primary and community care costs (in addition to the 
secondary care costs) and consequences (quality-adjusted 
life-years (QALY)) for any participant with an hs-troponin 
below the LoD. This applies to both trial groups. Data 
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collection for the additional primary and community care 
costs will be based on participant self-report following 
administration of a structured resource use questionnaire 
at 30 days and standard methods of unit costing. QALYs 
will be derived from the EQ-5D (5-level version) using the 
set of preference weights recommended by NICE at the 
time of analysis.24
Integrated qualitative study
The qualitative component of this trial aims to explore 
the patients’ experiences of the ED, the concerns or 
anxieties they might have and how best to word patient 
discharge information. To explore the acceptability of 
the LoDED strategy to participants and inform patient 
discharge information resources, a qualitative research 
assistant will undertake semistructured interviews with a 
sample of intervention participants. At 30-day follow-up 
contact, all participants with hs-troponin levels below the 
LoD will be invited to participate in an interview. From 
those participants who consent to interview, a purposive 
sample will be selected across all sites to maximise varia-
tion in terms of age, sociodemographic status and gender. 
Up to 25 participant interviews (lasting approximately 
30 min) will be conducted by phone using a topic guide 
to explore experiences of the participant’s stay in ED, 
any concerns or anxieties they might have about being 
discharged early and how best to word and present the 
written patient discharge information. Consent to take 
part in the qualitative study will be collected before the 
interview is carried out. Topic guides will be developed 
from the literature, input from the patient advisory group 
and team discussions. Two general practitioners (GP) and 
practice nurse focus groups will be held towards the end 
of the recruitment period to explore their views about 
the information that they would like to be provided to 
patients who are discharged early. Findings from the 
participant interviews will contribute to these focus group 
discussions.
Interviews and focus groups will be recorded, tran-
scribed, anonymised and analysed using thematic 
methods facilitated by NVivo software (QSR Interna-
tional). Analysis will be ongoing and iterative. Transcripts 
will be coded and global themes developed from the 
codes. Two researchers will code a sample of transcripts 
independently, compare coding, discuss and resolve 
any discrepancies within the research team to achieve a 
coding consensus and ensure robust analysis.
safety and data monitoring
Observational data have shown the LoDED strategy has a 
very high diagnostic accuracy.11–17 However, no rule-out 
strategy is 100% accurate, therefore, although there is no 
formal data monitoring committee, adverse event data 
will be monitored by the Trial Steering Committee (TSC), 
to ensure safety. The TSC includes an independent stat-
istician, cardiologist, emergency physician (chair) and a 
patient and public representative and will meet on four 
occasions. All suspected SAEs will be reported, within 
24 hours of discovery, to the CTU who will notify the Chief 
Investigator (CI), the TSC and the trial sponsor. All SAEs 
will be followed up until resolution. If the SAE is consid-
ered a MACE, this will be indicated on the SAE form, 
and will be adjudicated at the end of the study. Following 
the initial report to the CI of any study-related SAEs, the 
CI will notify the chair of the TSC within 48 hours of 
the event. The chair will arrange an ad hoc meeting of 
the TSC to discuss the SAE, and agree to any actions as 
needed. The TSC and trial sponsor have the authority to 
stop the trial if any indication of harm is found.
The CTU data management team is responsible for 
data management, including data entry. Original CRF 
pages will be posted to the CTU at agreed time points for 
double-data entry onto an SQL Server database using a 
bespoke, password-protected website, designed and main-
tained by the CTU data programming team.
Ethics and dissemination
The trial complies with the Declaration of Helsinki and 
GCP guidelines. All eligible, willing participants will 
undergo written informed consent by GCP trained staff 
before taking part in the study. 
The results of the study will be applicable and of 
interest to emergency physicians, acute physicians, cardi-
ologists, GPs and patients. The CI and trial management 
group (TMG) will establish a writing committee which 
will be responsible for preparing scientific reports of the 
study findings. The aim will be to publish a primary manu-
script in a high-impact general medical journal, published 
as open access, with secondary analyses described in 
specialty journals. Primary findings will also be presented 
at key meetings, for example, the annual conference of 
the Royal College of Emergency Medicine, the European 
Society of Cardiology Annual Congress and the Interna-
tional Conference on Emergency Medicine.
Patient and public involvement
Patient and public involvement was ensured at all stages 
of trial design. A prospective quantitative survey of 278 
patients with chest pain, performed by our group, has 
previously demonstrated satisfaction with very early 
discharge.28 The intervention and primary outcome 
measure of safe early discharge were supported by our 
patient advisory group. The patient advisory group 
oversaw development, and approved all patient-facing 
materials, including PIS, consent forms and discharge 
information leaflets. There will be continued patient 
representation on the TMG, TSC and authorship. Lay 
summaries of trial results will be made freely available to 
participants and the wider public.
dIsCussIon
This trial of the LoDED strategy versus usual care is a 
pragmatic multicentre RCT aiming to establish the clin-
ical and cost-effectiveness of a novel rule-out strategy for 
patients with chest pain attending the ED using just a 
8 Carlton E, et al. BMJ Open 2018;8:e025339. doi:10.1136/bmjopen-2018-025339
Open access 
single blood test, combined with ECG findings. Should 
the LoDED strategy prove effective, in a way that is accept-
able to patients, it is likely to become widespread practice 
in those EDs with access to hs-troponin assays. This would 
have potential benefits to patients around the world, by 
providing early reassurance and a potential reduction in 
ED crowding by facilitating earlier discharge.
This is a pragmatic study, being carried out in an envi-
ronment where patients with chest pain are normally 
treated, with clinical assessment being undertaken by 
treating emergency clinicians. In addition, we have 
selected multiple sites with variable usual care pathways 
that use a range of commercially available hs-troponin 
assays. These elements of the study design will enhance 
the generalisability of the trial findings.
The trial has also been designed to meet its objectives 
and recruitment targets in the challenging ED environ-
ment using a carefully considered effect size and accrual 
rate, based on data from previous research. We believe 
the trial will therefore be able to deliver these objectives 
within the allocated time and resources. Previous and 
ongoing interventional trials in this area have chosen a 
step-wedged cluster randomised design which require a 
larger sample size than individual randomisation, and 
have had primary outcomes evaluating safety.18 29 Given 
the strength of observational data confirming the high 
diagnostic accuracy of the LoDED strategy, we have been 
able to focus on clinical effectiveness as a primary outcome 
and we have elected to use a parallel group design with 
1:1 randomisation. This has allowed us to maximise the 
efficiency of the trial.
Other rule-out strategies using a single blood test to 
facilitate early discharge have been considered.10 18 21 29 30 
However, the LoDED strategy may have advantages over 
these. First, the hs-troponin test can be applied, on 
arrival in the ED, independently of chest pain onset 
time across the study population. This sets it apart from 
alternative methods currently under evaluation such 
as HighSTEACS,29 which uses a higher Abbott hs-tro-
ponin I cut-off value. The HighSTEACS strategy cannot 
be applied in patients presenting less than 2 hours from 
symptom onset, which is likely to make it less applicable 
and effective than the LoDED strategy. Second, other 
alternative strategies, including those recommended by 
NICE, require the addition of a risk score such as TIMI.22 
This may act to reduce the proportion of patients suit-
able for early discharge when compared with the LoDED 
strategy.
ConClusIons
The LoDED trial will seek to determine whether the 
LoDED strategy works when implemented in practice, 
with clinicians discharging patients early in significant 
numbers, without rebound increases in downstream 
costs and in a way that is acceptable to patients. It is an 
important trial for patients with chest pain presenting 
to the ED and the clinicians involved in their care. If we 
demonstrate that the LoDED strategy avoids the need 
for prolonged assessment in an extra 9% of patients 
or more, in a way that is cost-effective and acceptable 
to patients, we anticipate widespread uptake of the 
strategy, leading to earlier reassurance for patients and 
substantial cost savings for the health system.
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